PMV Pharmaceuticals, Inc. (PMVP)

Several events impacted PMV Pharmaceuticals, Inc.'s stock price in the past six months. Updated interim data from the PYNNACLE Phase 2 trial for rezatapopt showed positive results, leading to a stock increase. The company presented trial data at a conference and held an investor webinar. PMV Pharmaceuticals reported its Third Quarter 2025 Financial Results, including a net loss and projected cash reserves. The company participated in investor conferences. OrbiMed Advisors LLC sold PMV Pharma shares, and insiders sold more company stock than they bought.

As a clinical-stage pharmaceutical company, PMV Pharmaceuticals, Inc. currently has no commercialized products generating revenue, so there is no existing product demand to analyze for seasonality. Demand would primarily be driven by medical need and prescription rates once a product is commercialized.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule, tumor-agnostic therapies targeting p53 mutations in cancer. Their lead product candidate, rezatapopt (PC14586), is an orally available p53 reactivator designed to correct p53 misfolding caused by the p53 Y220C mutation. The company is clinical-stage and currently generates no product revenue.

PMV Pharmaceuticals, Inc. is headquartered in Princeton, New Jersey, United States, and its primary operations appear to be based out of this location.

PMV Pharmaceuticals' brand reputation has been positively influenced by the progress of its clinical development, particularly the positive interim data from the PYNNACLE Phase 2 trial for rezatapopt. The company operates in a highly regarded area of cancer research, focusing on addressing p53 mutations. There were no widely reported events that significantly negatively impacted the company's brand reputation.

PMV Pharmaceuticals, Inc. has a mixed ownership structure, with a significant portion held by institutional investors, ranging from 61.16% to 90.20%. Major institutional owners include OrbiMed Advisors LLC, InterWest Partners LLC, and others. Insiders hold approximately 0.6% to 12.71% of the shares, and the general public holds approximately 12% to 22.36%.